Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | FES | P07332 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291418 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4KCNH2SLC6A3PER2 | |
| SCHEMBL20249152 | 0.84 | SLC6A2 (0.36) | SLC6A2SLC6A4KCNH2SLC6A3PER2 | |
| SCHEMBL20255410 | 0.76 | FFAR2 (0.35) | GAA | |
| SCHEMBL20037822 | 0.70 | GRIA2 (0.36) | MEN1KMT2AKDM4E | |
| SCHEMBL20037789 | 0.70 | SMN1; SMN2 (0.46) | PER2GAALMNA | |
| SCHEMBL20037844 | 0.70 | SMN1; SMN2 (0.46) | PER2GAALMNA | |
| SCHEMBL31428916 | 0.65 | KCNH2 (0.51) | SLC6A2SLC6A4KCNH2SLC6A3PER2 | |
| SCHEMBL20847588 | 0.63 | HDAC6 (0.53) | ELOVL1MEN1KMT2A | |
| SCHEMBL24975790 | 0.63 | SLC6A2 (0.48) | SLC6A2SLC6A4KCNH2SLC6A3PER2 | |
| SCHEMBL31428800 | 0.63 | SLC6A2 (0.48) | SLC6A2SLC6A4KCNH2SLC6A3PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SLC6A2 2659/4885SLC6A4 1825/4885KCNH2 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.